Microba Life Sciences Limited (ASX:MAP)

Market Cap	51.50M
Revenue (ttm)	16.90M
Net Income (ttm)	-14.19M
Shares Out	447.85M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	437,751
Average Volume	385,535
Open	0.0840
Previous Close	0.0840
Day's Range	0.0840 - 0.0870
52-Week Range	0.0820 - 0.3250
Beta	2.52
RSI	24.48
Earnings Date	Sep 8, 2025

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore, a diagnostics under the brand Co-Biome ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In 2024, Microba Life Sciences's revenue was 12.09 million, an increase of 123.06% compared to the previous year's 5.42 million. Losses were -19.94 million, 57.2% more than in 2023.